Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Biogen, AGTC team up in gene therapy deal; deal terminated

Executive Summary

Biogen Inc. received worldwide rights to commercialize Applied Genetic Technologies Corp.'s Phase I X-linked retinoschisis (XLRS) gene therapy program and preclinical candidate for X-linked retinitis pigmentosa (XLRP).
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • Intra-Biotech Deal
    • Includes Royalty or Profit Split Information
    • Includes Equity
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register